Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Share-based Compensation (2017 - 2024)

Solid Biosciences' Share-based Compensation history spans 8 years, with the latest figure at $3.8 million for Q4 2024.

  • For Q4 2024, Share-based Compensation rose 97.16% year-over-year to $3.8 million; the TTM value through Dec 2024 reached $10.5 million, up 37.95%, while the annual FY2024 figure was $10.5 million, 37.95% up from the prior year.
  • Share-based Compensation for Q4 2024 was $3.8 million at Solid Biosciences, up from $3.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.8 million in Q4 2024 and bottomed at $1.5 million in Q3 2022.
  • The 5-year median for Share-based Compensation is $2.6 million (2020), against an average of $2.5 million.
  • The largest annual shift saw Share-based Compensation tumbled 55.39% in 2022 before it skyrocketed 97.16% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $2.5 million in 2020, then surged by 35.62% to $3.4 million in 2021, then tumbled by 53.53% to $1.6 million in 2022, then rose by 22.12% to $1.9 million in 2023, then surged by 97.16% to $3.8 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Share-based Compensation are $3.8 million (Q4 2024), $3.0 million (Q3 2024), and $2.1 million (Q2 2024).